Overview

A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent

Status:
Recruiting

Trial end date:
2022-09-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to demonstrate the safety profile of daratumumab in routine clinical practice when given as monotherapy in Indian participants with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent.

Phase:

Phase 4

Details

Lead Sponsor:

Johnson & Johnson Private Limited

Treatments:

Antibodies, Monoclonal
Daratumumab
Immunologic Factors
Proteasome Inhibitors